Opus Genetics, Inc. (IRD) Income Statement
IRD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIRD revenue and net income
Where IRD's revenue goes
2025Each bar shows an amount and its share of revenue. IRD kept −349.3% of revenue as net income.
IRD profit margins
IRD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +29.1% | −29.1% | — | — |
| Gross profit | +29.1% | −29.1% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IRD quarterly EPS vs estimates
Opus Genetics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.14).
IRD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 | $0 | $0 |
| Cost of revenue | $53,000 | $10,000 | $6,000 | $4,000 | $4,000 | $8,000 | — |
| Gross profit | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 | −$8,000 | — |
| Research & development | $30.8M | $26.9M | $17.7M | $14.4M | $15.2M | $6.6M | $2.4M |
| Sales, general & admin | $22.0M | $18.2M | $12.0M | $7.3M | $8.1M | $2.8M | $1.8M |
| Total operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M | $20.0M | $4.2M |
| Operating income | −$38.6M | −$62.1M | −$10.6M | $18.2M | −$22.7M | −$20.0M | −$4.2M |
| Interest expense | $1.5M | $0 | $1.3M | $9,000 | $2,000 | $6.8M | $1.4M |
| Income before taxes | −$49.6M | −$57.5M | −$10.0M | $18.2M | −$56.7M | −$24.6M | −$6.2M |
| Income taxes | — | — | $12,000 | $315,000 | — | — | — |
| Net income | −$49.6M | −$57.5M | −$10.0M | $17.9M | −$56.7M | −$24.6M | −$6.2M |
| EBITDA | −$48.1M | −$57.5M | −$10.0M | $18.2M | −$56.7M | −$17.8M | −$4.8M |
| EPS (diluted) | −$0.90 | −$2.15 | −$0.48 | $0.87 | −$1.59 | −$8.11 | −$10.33 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating margin | −271.9% | −564.7% | −55.5% | 45.7% | −3,854.8% | — | — |
| Net margin | −349.3% | −523.4% | −52.4% | 44.9% | −9,625.3% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $755,000 | $2.2M | $3.9M | $3.1M | $2.9M | $4.4M | $4.3M | $3.9M | $1.1M | $1.7M | $1.7M | $11.9M |
| Cost of revenue | $0 | $13,000 | $13,000 | $13,000 | $6.0M | $13,000 | $7.8M | $0 | $0 | $0 | $4.7M | $1,000 |
| Gross profit | $755,000 | $2.1M | $3.9M | $3.1M | −$3.1M | $4.4M | −$3.5M | $3.9M | $1.1M | $1.7M | −$3.0M | $11.9M |
| Research & development | $11.2M | $10.6M | $10.4M | $6.4M | $6.0M | $8.0M | $7.0M | $9.0M | $6.1M | $4.7M | $3.8M | $3.5M |
| Sales, general & admin | $6.0M | $5.9M | $4.9M | $5.0M | $5.8M | $6.3M | $7.3M | $2.9M | $3.4M | $4.7M | $3.3M | $2.1M |
| Total operating expenses | $17.2M | $16.5M | $15.3M | $11.4M | $5.8M | $14.3M | $34.6M | $11.9M | $9.4M | $9.4M | $2.4M | $5.5M |
| Operating income | −$16.5M | −$14.4M | −$11.5M | −$8.3M | −$8.9M | −$9.9M | −$38.0M | −$8.0M | −$8.3M | −$7.7M | −$5.4M | $6.4M |
| Interest income | — | — | — | — | $35,000 | — | — | $500,000 | — | $600,000 | — | — |
| Interest expense | $531,000 | $651,000 | $1.4M | $68,000 | $35,000 | $1.4M | $0 | $0 | $0 | $0 | $0 | $1.3M |
| Income before taxes | −$8.1M | −$65.5M | −$16.5M | −$17.5M | −$7.4M | −$8.2M | −$35.1M | −$7.5M | −$7.8M | −$7.1M | −$4.8M | $5.6M |
| Income taxes | — | — | — | — | — | — | — | — | — | — | −$2,000 | $14,000 |
| Net income | −$8.1M | −$65.5M | −$16.5M | −$17.5M | −$7.4M | −$8.2M | −$35.1M | −$7.5M | −$7.8M | −$7.1M | −$4.8M | $5.6M |
| EBITDA | −$7.6M | −$64.9M | −$15.1M | −$17.4M | −$7.4M | −$6.8M | −$10.0M | −$7.5M | −$7.8M | −$7.1M | −$4.8M | $6.9M |
| EPS (diluted) | −$0.14 | −$0.75 | −$0.21 | −$0.25 | −$0.12 | −$0.32 | −$1.27 | −$0.29 | −$0.30 | −$0.29 | −$0.21 | $0.25 |
| Gross margin | 100.0% | 99.4% | 100.0% | 100.0% | −109.0% | 100.0% | −80.8% | 100.0% | 100.0% | 100.0% | −177.8% | 100.0% |
| Operating margin | −2,182.8% | −665.9% | −296.3% | −269.9% | −309.0% | −227.2% | −884.0% | −207.1% | −748.9% | −450.5% | −321.1% | 53.5% |
| Net margin | −1,072.6% | −3,038.2% | −427.5% | −566.9% | −257.5% | −187.5% | −816.7% | −194.6% | −698.3% | −415.3% | −283.6% | 46.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IRD's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IRD financial results
In fiscal year 2025 (ended December 31, 2025), Opus Genetics reported revenue of $14.2 million, up 29.1% from the year before. It had a net loss of $49.6 million, a net profit margin of −349.3%. Diluted earnings per share came to −$0.90.
See the IRD stock overview for the latest quote and news, or the IRD chart for price history and technical indicators.
IRD income statement FAQ
What is Opus Genetics's annual revenue?
Opus Genetics reported total revenue of $14.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 29.1% from $11.0 million the previous year.
Is Opus Genetics profitable?
No. Opus Genetics reported a net loss of $49.6 million in fiscal 2025, a net profit margin of −349.3%; its operating margin was −271.9%.
What is Opus Genetics's gross margin?
Opus Genetics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Opus Genetics kept $100 after the direct cost of its products and services.
How much does Opus Genetics spend on research and development?
Opus Genetics spent $30.8 million on research and development in fiscal 2025, 217.0% of revenue.
What are Opus Genetics's earnings per share?
Opus Genetics earned $-0.90 per diluted share in fiscal 2025, compared with $-2.15 a year earlier.
When will Opus Genetics report its next earnings?
Opus Genetics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Opus Genetics's fiscal year end?
Opus Genetics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.